PATENT CLAIM ANALYSIS

Application Number: 16032812
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["436", "547000"]

Abstract:
The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.

Claim (Index 3):
The method of  claim 2 , wherein said antibody is an antibody specific for CD3, an antibody specific to CD4, an antibody specific to CD52, an antibody specific to TNF alpha, or an antibody specific to interferon gamma IFN-\u03b3.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 95.0
- Lexical Diversity: 1.13043
- Patent Class: 436.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['10807414', '14812566', '11034262', '09765644', '14403523']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6729898696324932
- 35 USC 102 Novelty (BERT): 0.518826748556632
- Combined Prediction Score: 0.6575735575249071
- Mean Citation Score: 304.389314
- Max Citation Score: 318.16144
- Similarity Product: 201.3542674961376

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test